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We compared the functional outcome of Isl-1+ cardiac progenitors, CD90+ bone marrow-derived progenitor cells, and the
combination of the two in a rat myocardial infarction (MI) model. Isl-1+ cells were isolated from embryonic day 12.5 (E12.5)
rat hearts and expanded in vitro. Thy-1+/CD90+ cells were isolated from the bone marrow of adult Sprague-Dawley rats by
immunomagnetic cell sorting. Six-week-old female Sprague-Dawley rats underwent permanent left anterior descending (LAD)
coronary artery ligation and received intramyocardial injection of either saline, Isl-1+ cells, CD90+ cells, or a combination of
Isl-1+ and CD90+ cells, at the time of infarction. Cells were delivered transepicardially to the peri-infarct zone. Left
ventricular function was assessed by transthoracic echocardiography at 1- and 4-week post-MI and by Millar catheterization
(-dP/dt and +dP/dt) at 4-week post-MI. Fluorescence in situ hybridization (Isl-1+cells) and monochrystalline iron oxide
nanoparticles labeling (MION; CD90+ cells) were performed to assess biodistribution of transplanted cells. Only the
combination of cells demonstrated a significant improvement of cardiac function as assessed by anterior wall contractility,
dP/dt (max), and dP/dt (min), compared to Isl-1+ or CD90+ cell monotherapies. In the combination cell group, viable cells
were detected at week 4 when anterior wall motion was completely restored. In conclusion, the combination of Isl-1+ cardiac
progenitors and adult bone marrow-derived CD90+ cells shows prolonged and robust myocardial tissue repair and provides
support for the use of complementary cell populations to enhance myocardial repair.
1. Introduction
Despite recent advances in medical therapy, ischemic heart
disease remains one of the leading causes of morbidity and
mortality worldwide. Since MI results in irreversible damage
to the left ventricular wall leading to remodeling and dys-
function, development of treatments is aimed at repairing
the muscular tissue and vascular network is now considered
a major therapeutic challenge.
The optimal stem cell type for regenerating the heart has
been under debate for many years. The adult heart contains
its own reservoir of endogenous cardiac stem cells that can,
to some extent, generate new cardiomyocytes [1, 2]. Cardiac
precursors have been generated from c-kit+ [1–4], Sca-1+
[5, 6], side population (SP) cells expressing Abcg2 [7],
and first and second heart field cells (Tbx5+ and LIM
homeodomain transcription factor Islet-1 (Isl-1), respec-
tively) [2, 8–11]. Isl1 was found to distinguish this key stem
cell population derived from the second heart field [8].
Isl1+ progenitor cells have been shown to migrate into the
developing heart, giving rise to the outflow tract, the majority
of the cells in the right ventricle and the atria, and a portion
of cells in the left ventricle [8]. In vivo cell lineage tracing in
mouse embryos using the Cre-loxP strategy has confirmed
that Isl1+ progenitors contribute to more than two-thirds of
the cells in the embryonic heart [11–13]. Taken together,
these studies provide evidence that Isl1+ progenitors repre-
sent true cardiovascular precursors giving rise to cardiac
muscle, parts of the conduction system, and endothelial/s-
mooth muscle cells throughout the proximal aorta, pulmo-
nary trunk, and the branches of the proximal left and right
coronary arteries. Previously, it was reported that Isl1 expres-
sion was downregulated as soon as the Isl1+ cells enter the
heart [8, 10]. However, recently evidence of their presence
in the adult heart [10] has been demonstrated suggesting that
this population could be utilized for allogeneic and perhaps
even autologous stem cell therapy.
CD90+ cells represent a subfraction [14] of mesenchymal
stem cells (MSCs). MSCs, mediators of immune modulation
and suppression, are able to improve transplant engraftment,
treat graft-versus-host disease, and suppress T cell responses
and have shown great therapeutic potential [15]. Their
immune modulatory capacity is mediated through cell-to-
cell contact and cytokine secretion. Exogenous CD90+ cells
have also been shown to enhance vascular repair paracrine
regulators of blood vessel growth. MSCs have been widely
used for cardiac tissue repair either alone [16–24] or in
combination with adult c-kit+ cardiac progenitor cells
(CPCs) [25, 26].
With the advent, subsequent wide spread utilization of
iPSC technology and now initiation of clinical trials utilizing
these cells, the possibility of generating large numbers of cells
with fetal phenotypes and surface markers is now feasible.
Embracing this notion of the future feasibility of utilizing
cells with a fetal phenotype, we tested the efficacy of Isl1+
progenitor cells in myocardial repair following MI in a rat
model. We utilize these cells alone and in combination with
CD90+ cells postulating that because these unique popula-
tions target different pathogenic mechanisms/pathways, they
would be more effective in combination. CD90+ would serve
to modulate local inflammation at sites of myocardial injury,
while exogenous cardiac Isl-1+ stem cells would foster direct
cardiomyocyte repair.
2. Materials and Methods
2.1. Cardiac Progenitor Cell Isolation. Isl1+ cells were isolated
from rat fetal hearts by differential plating by adaptation of a
mouse cell isolation protocol [11] and expanded in culture.
Briefly, the hearts from embryonic day 12.5 (ED12.5) rats
were cut into four pieces, washed repeatedly in ice-cold
Hank’s balanced salt solution (HBSS) without Ca2+, and pre-
digested overnight in 0.5mg/ml trypsin in HBSS at 4°C,
under constant shaking, to remove blood and dead cells. Car-
diac cells were obtained by four rounds of 10min digestions
with 240U/ml collagenase type II (Worthington, Lakewood,
NJ) in HBSS at 37°C. The mesenchymal cell fraction contain-
ing most Isl-1+ progenitor cells was separated from myocytes
and endothelial cells by two rounds of 1-hour differential
plating on plastic in DMEM/M199 (4 : 1 ratio) medium con-
taining 10% horse serum and 5% fetal bovine serum at 37°C
in the presence of 5% CO2. Under these conditions, preferen-
tially mesenchymal and precursor cells attach on plastic.
After rigorous washing to remove nonadherent cells, the
remaining cardiac mesenchymal cells (CMC) and cardio-
blasts were cultured for 48h in DMEM containing penicillin
(100U/ml), streptomycin (100 μg/ml), HEPES (25mM),
glutamine (2mM), 10% newborn calf serum, and 5% fetal
bovine serum (FBS). On the second day in culture, medium
was changed to DMEM/F12 containing B27 supplement
(StemCell Technologies, Inc.) and 10% FBS to stimulate
Isl-1+ progenitor growth.
2.2. CD90+ Cell Isolation. Bone marrow preparations from
tibiae and femurs of adult male Sprague-Dawley rats
(Charles River Laboratories International, Inc., Wilmington,
MA) were obtained aseptically, and after a series of washes
and centrifugations, a Thy-1+-enriched cell suspension was
obtained by immunomagnetic cell selection using a custom-
ized kit (StemCell Technologies, Inc., Vancouver, Canada)
as per the manufacturer’s protocol.
Briefly, whole bone marrow was flushed out of the bones
with ice-cold PBS using a 27G needle. The mixture was then
centrifuged at 340 g for 10 minutes and the supernatant dis-
carded while the pellet was suspended in 2% FBS and 1mM
EDTA PBS. The resulting cell suspension underwent a nega-
tive selection step in which CD4+, CD5+, CD8a+, and OX43+
cells were discarded followed by a positive selection step in
which the cell suspension was enriched for CD90+/Thy-1+
cells using a phycoerythrin- (PE-) conjugated mouse anti-
rat CD90/Thy-1 antibody (Abcam, Cambridge, MA) and a
PE selection kit (StemCell Technologies, Inc.).
2.3. Monochrystalline Iron Oxide Nanoparticle (MION)
Labeling. For cell tracking purposes, Isl-1+ cells were labeled
with monochrystalline iron oxide nanoparticles (MION)
as previously described [27]. Briefly, confluent cultures of
Isl-1+ cells were incubated in 10% fetal bovine serum-
supplemented medium with 20 μM (1 : 500 dilution) of
MIONs in 5% CO2 at 37
°C overnight. After incubation, cells
were washed two times in PBS before trypsinization in order
to remove the noninternalized MIONs.
An aliquot of Isl-1+ cells was seeded on chamber slides and
used for Prussian Blue staining to evaluate MION cell uptake.
2.4. Reverse Transcription-Polymerase Chain Reaction. Cell
extract total mRNA was isolated (RNeasy kit; Qiagen Inc.)
as per the manufacturer’s instructions. The mRNA was
then transcribed (iScript™ cDNA Synthesis Kit; Bio-Rad,
Hercules, CA), and real-time PCR was performed (ABI
Master Mix; ABI Biosystems, Foster City, CA). Primers for
rat ISL-1, Nkx2.5, and GATA-4 were purchased from ABI
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Biosystems. All samples were normalized to beta actin (ABI
Biosystems) for 60 cycles and all reactions were performed
in triplicate.
2.5. Immunofluorescence. To assess the purity of the cells, we
performed immunofluorescence studies. All the steps, unless
otherwise indicated, were performed at room temperature.
Cultured cells were fixed in 4% buffered paraformaldehyde
(PFA) for 10 minutes and then washed in PBS three times.
After a common permeabilization step in 0.2% Triton
X-100 in PBS for 10minutes and an additional three washes
in PBS, one set of samples was treated as follows: nonspecific
binding was blocked by incubation in 10% normal goat
serum for 1 hour and then incubated overnight at 4°C in rab-
bit anti-Islet-1 (Abcam, Cat. # ab20670, 2 μg/ml) or rabbit
anti-GATA-4 (Abcam, Cat. # ab61170, dil. 1 : 500). After
three additional washes in PBS, samples were incubated for
1 hour in FITC-conjugated goat anti-rabbit IgG antibody
(Vector Laboratories, Burlingame, CA, Cat. # FI-1000,
10 μg/ml). Another set of samples was blocked in 10% nor-
mal rabbit serum for 1 hour and then incubated in goat
anti-Nkx2.5 (Santa Cruz, Cat. # sc-8697, dil. 1 : 50) overnight
at 4°C. Then, samples were incubated in AlexaFluor® 488-
conjugated rabbit anti-goat antibody (Invitrogen, Cat # A-
11078, dil. 1 : 200) for 1 hour. All the samples were then
washed three times in PBS and mounted with VECTA-
SHIELD® antifade mounting medium with DAPI for nuclear
staining (Vector Laboratories, Cat. # H-1200).
2.6. Detection of MION Labeled Isl-1+ Cells (Prussian Blue
Staining). The excised hearts were embedded in paraffin
and sliced into 4 μm thick sections for histological analysis.
After deparaffinization with xylene, samples were rehydrated
through an ethanol gradient and rinsed in distilled water.
After the rehydration steps, some sections of each heart were
stained with Prussian Blue to examine the biodistribution of
MION-labeled CSC. Briefly, tissue sections were washed 3
times with PBS, incubated for 30 minutes with 5% potassium
ferrocyanide (Sigma-Aldrich, St. Louis, MO, USA) in 5%
hydrochloric acid, and rewashed and counterstained with
nuclear fast red (Sigma) for 20 minutes.
2.7. Western Blot Studies. Isolated CPC were lysed with
RIPA lysis buffer (Sigma-Aldrich, St. Louis, MO), and cell
suspension was centrifuged at 15,000 g to pellet cell debris.
Protein concentration was measured in the supernate using
the BCA Protein Assay Reagent (Pierce, Rockford, IL,
USA) at an absorbance of 562 nm as per the manufac-
turer’s directions.
Electrophoresis was performed using a discontinuous
Tris-glycine buffer system. Proteins were suspended in
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) buffer (20mM Tris-HCl, 0.2M glycine) and
boiled for 5min. Forty micrograms of protein was loaded
in each well of a 10% SDS polyacrylamide gel. Gels were
immediately electrotransferred to polyvinylidene difluoride
(PVDF) membranes (Millipore, Bedford, MA, USA) at
60V for 1 h by means of a semidry transfer system (Bio-
Rad Lab., Hercules, CA, USA) (transfer buffer: 20mM
Tris-HCl, 0.2M glycine, 20% MeOH). Membranes were
blocked with 5% nonfat dry milk in TBS/Tween buffer
(blocking buffer, BB) (25mM Tris-HCl, 0.14M NaCl, 2%
Tween20; Bio-Rad Lab) for 1 hour at room temperature.
Membranes were then cut in strips, and each lane was incu-
bated with either rabbit anti-ISL-1 (Aviva Systems Biology,
San Diego, CA) dil. 1 : 1000, goat anti-CSX1/NKX2-5 (Ever-
est Biotech Ltd., Upper Heyford Oxfordshire, UK), mouse
anti-GATA4 (Abcam Inc., Cambridge, MA) dil 1 : 500, rab-
bit anti-c-kit (Novus Biologicals, Littleton, CO) dil 1 : 500,
rabbit anti-sarcomeric Alpha Actinin (Abcam) dil 1 : 500,
mouse anti-cardiac Troponin I (Abcam) dil. 1 : 500, or rab-
bit anti-Connexin 43 (Invitrogen, Camarillo, CA) (4 μg/ml)
in blocking buffer. Membranes were then washed three
times, 5 minutes each time, with TBS containing 0.05%
Tween-20 followed by incubation with one of the following
HRP-conjugated secondary antibodies: goat anti-rabbit
(1 : 200), goat anti-mouse (1 : 200), and donkey anti-goat
(1 : 200) (Santa Cruz Biotechnology, Santa Cruz, CA) at
room temperature for 1 hour. Following three washes as
above, proteins were revealed by enhanced chemiolumines-
cence (ECL) (Amersham, Buckinghamshire, England) were
exposed to film (Hyperfilm ECL; Amersham). The film
was scanned, and protein band concentrations were quanti-
fied by integrated optical density using NIH ImageJ soft-
ware (NIH).
2.8. Detection and Quantification of Fibrotic Tissue. Intersti-
tial fibrosis was assessed on 5 μm thick paraffin embedded
tissue sections by Masson’s trichrome staining (Accustain™
Trichrome (Masson), kit # HT-15, Sigma-Aldrich, St. Louis,
MO.) as per the manufacturer’s instructions. Stained glass
slides were optically scanned using a ScanScope XT digital
slide scanner (Aperio Technologies, Inc., Vista, CA) to create
whole-slide digital planar image files at 0.5 μm/pixel resolu-
tion. Quantification of fibrotic areas was achieved using
Aperio ImageScope software. The standard positive pixel
algorithm was altered to read the Masson’s Trichrome
stained slides (hue value: 0.62; hue width 0.4; color saturation
threshold: 0.005). The total area was then selected by tracing
the outer margin of the tissue section using the pen tool while
the void areas (right and left ventricles) were subtracted by
tracing them with the negative pen tool. After the analysis
was run, the markup image, showing the contractile tissue
in blue and the fibrosis in red, was generated, and the result-
ing values were displayed in the annotations window and
appeared as positivity = Npositive/Ntotal. Values were then
multiplied by 100 to calculate the percentage of total area.
Values were then expressed as mean ± SEM. Wall thickness
was measured also with ImageScope using the ruler tool. In
each tissue section, seven different measurements were
taken across the infarcted area (left ventricle anterior wall)
and averaged.
2.9. Y-Chromosome Fluorescence In Situ Hybridization. Five-
micrometer sections of PFA-fixed, paraffin-embedded car-
diac tissue were deparaffinized in xylene, rehydrated through
a graded ethanol series, postfixed in 10% neutral-buffered
formalin (NBF) for 10 minutes, and rinsed in water before
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air drying for one hour. Slides were pretreated in 0.2N HCl
for 30 minutes at room temperature and then washed twice
for 5 minutes in ddH2O. Antigen retrieval was performed by
immersing slides in 1M sodium thiocyanate for 30 minutes
at 85°C. The slides were removed from the retrieval solution
and rinsed thoroughly in ddH2O. Sections were digested in
4mg/ml pepsin (Sigma) diluted in 0.9% NaCl (pH 2.0) for
55 minutes at 37°C. Digested sections were removed and
immediately rinsed in water, equilibrated in 2× saline-
sodium citrate (SSC), and dehydrated through a graded eth-
anol series. Ten microliters of rat Y + chromosome 12 probe
(Cambio Ltd.; Cambridge, UK) was denatured for 10
minutes in a 75°C water bath and allowed to preanneal at
37°C for 45 minutes prior to being applied to the prepared
section and topped with a 22 × 22 coverslip. Slides were
sealed with rubber cement, denatured at 75°C for 6 minutes,
and hybridized overnight at 37°C in a Hybrite oven (Vysis,
Downers Grove, IL). After hybridization, coverslips were
removed and sections were washed in 3 changes of 50% for-
mamide/2 × SSC, followed by 2 × SSC, and 4 × SSC + 0:1%
Igepal (NP-40) at 46°C for 7 minutes each. Slides were air
dried at RT in the dark and mounted with Vectashield®
mounting medium with DAPI (Vector Laboratories).
2.10. Immunostaining for von Willebrand Factor. All steps
were performed using DAKO Autostainer Plus System
(Agilent, Santa Clara, CA). Five-micrometer sections of
PFA-fixed, paraffin-embedded cardiac tissue were processed
for immunohistochemistry using DAKO PT Link (Agilent).
Briefly, samples were deparaffinized in xylene and rehydrated
through a graded ethanol series. Antigen retrieval was
achieved using EnVision FLEX high pH target retrieval solu-
tion (Agilent). The cycle begins at 85°C and is heated to
100°C for 20 minutes and then cooled back to 85°C. The
slides were then removed from the retrieval solution and
rinsed thoroughly in Dako wash buffer. Samples were then
incubated for 10min in H2O2 (Thermo Fisher Scientific
Waltham, MA), rinsed in Dako wash buffer (Agilent), and
incubated for 15 minutes in serum-free Dako protein block
to inhibit nonspecific staining. von Willebrand factor anti-
bodies (Cat. # IR 527 TRS; DAKO-Agilent) were applied
for 20 minutes at room temperature, and after a quick rinse
with wash buffer, samples were incubated with EnVision
FLEX HRP (Cat. # K8000; Dako-Agilent) for 10 minutes.
After another rinse in wash buffer, samples were incubated
for 10 minutes in diaminobenzidine (DAB) followed by a
quick rinse and two baths of 5 minutes in hematoxylin.
Samples were then rinsed in DI H2O and dehydrated through
a graded ethanol series and mounted.
2.11. Animal Studies. All protocols conformed to the National
Institutes of Health (NIH) guidelines. Animals received care
in compliance with the Principles of Laboratory Animal
Care. All rats were housed with access to food and water ad
libitum on a 12h/12 h light/dark cycle.
2.12. LAD Ligation. Six-week-old Sprague-Dawley rats
(Charles River Laboratories, Inc., Wilmington, MA) were ini-
tially anesthetized with 5% isoflurane. Endotracheal intuba-
tion was then performed by insertion of an endotracheal
tube (polyethylene size 90; PE 90), and mechanical ventila-
tion was then achieved by connecting the endotracheal tube
to a Harvard Model 683 Small Animal Ventilator (Harvard
Apparatus, Holliston, MA).
Throughout the duration of the surgery, rats were
exposed to a 3% isoflurane flow.
After the LAD coronary artery was exposed through a 4th
intercostal left lateral thoracotomy, the pericardium was cut
open. The LAD coronary artery was ligated with a 5-0 silk
suture at 1-2mm from the left auricle, with slight excursion
of the cross of the left auricle and right conus branch. A suc-
cessful MI was established upon sudden discoloration of the
anterior wall of the left ventricle.
After LAD ligation, rats were randomly assigned to one
of the following groups and received intramyocardial injec-
tion (100 μl) of either 0.9% NaCl solution (n = 13) (saline),
in vitro-expanded rat fetal Isl-1+ cells (1 × 106) (n = 12)
(Isl-1), freshly isolated CD90+ cells (1 × 106) (n = 10)
(CD90), or a combination of Isl-1+ and CD90+ cells(Isl-
1/CD90) (1 × 106/ea:) (n = 9), at time of infarction delivered
transepicardially to the peri-infarct zone. An aliquot of Isl-1+
cells was plated for purity assessment by immunohisto-
chemistry and showed a near to 100% positivity for Isl-1
(Figure 1(a)). A fifth group (sham) (n = 5) was composed
by age/sex-matched rats which did not receive any surgery
or injections. All rats were euthanized 4-week post-MI
with pentobarbital (50mg/kg). Cardiac tissue was quickly
harvested and processed for histology.
2.13. Echocardiography. Rats were lightly anesthetized with
isoflurane (2%) O2 mixture via a face mask attached to a
gas vaporizer during spontaneous ventilation. Animals were
imaged in a shallow left lateral supine position using a GE
vivid7 ultrasound machine with a 12MHz transducer (GE
Healthcare, NJ, USA) to assess the ventricular dimensions
and cardiac function. ECG electrodes were placed for timing
of intracardiac events. In short-axis view, using 2D and M
mode images, posterior wall thickness, end-systolic and
end-diastolic dimensions, and % fractional shortening were
measured and averaged from 3 cardiac cycles. 2D guided
pulsed Doppler recordings of mitral inflow were obtained
in the apical 4-chamber view with the sample volume placed
at the tips of the mitral leaflets in diastole. Peak flow velocities
of early filling (E) and late filling (A), E/A ratio, rate of
decrease in early flow (Edecslope), and deceleration time
(Edectime) were averaged from 6 consecutive cycles. Load-
independent spectral tissue Doppler measurements from
the septal mitral annular wall were assessed for E′ (myocar-
dial elongation during early filling), A’ (myocardial wall
motion during late filling), E’/A’, and E/E’ (estimation of
LV filling pressures). All echocardiographic studies were per-
formed and analyzed by an investigator/echocardiographer
that was masked to the treatment groups.
Imaging required 10 minutes per rat. Respiratory rate
(e.g., adequate diaphragm excursion) was followed by clinical
observation throughout the scanning period. Prior to anes-
thesia induction, all animals were weighed.
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Figure 1: Characterization of isolated embryonic cardiac stem cells in culture. (a)–(c) Immunofluorescence micrographs showing cells
isolated from E12.5 rat hearts expressing various cardiac progenitor markers: Isl-1 (a), Nkx2.5 (b), and GATA-4 (c). (d) Blank, in which
the primary antibody was omitted. (e) Bright field and superimposed fluorescence micrograph of cells stained with Prussian Blue
demonstrate incorporation of MION in the cytoplasm A close-up view of (e) is shown (e’). Light blue: nuclei (DAPI); dark blue: MION.
(f) Western blot analysis of cell extract confirmed expression of various cardiac markers (Islet-1, Nkx2.5, GATA-4, sarcomeric α-actinin,
cardiac troponin I, connexin-43). Cells were identified as c-kit-.(g) Real-time PCR analysis showed that, after several passages in culture,
isolated cells lost expression of GATA-4.
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2.14. Direct Hemodynamic Evaluation. Four weeks after MI
induction, rats were anaesthetized initially with a 5% isoflur-
ane/O2 mixture in an induction box and then kept asleep
with a 2.5% isoflurane/O2 mixture via a face mask attached
to a gas vaporizer during spontaneous ventilation. Rats were
placed in the supine position, and body temperature was
maintained at 37°C by a heating pad throughout the experi-
ment. Left ventricular function was measured using a pres-
sure catheter (SPR-320; Millar Instruments, Houston, TX,
USA), which was inserted into the right carotid artery. After
10min stabilization, arterial blood pressure was recorded for
10min. Then, the catheter was advanced into the left ventri-
cle and stabilized for 5min. The waveform was used to con-
firm the positioning of catheter in the LV. Left ventricular
end-diastolic pressure (LVEDP) was continuously recorded
for 10min by the Powerlab Chart 4 software system (ADIn-
struments Inc., Colorado Springs, CO, USA).
2.15. Statistical Analysis. All experiments were repeated at
least three times. The hemodynamic evaluation was assessed
using a Student’s t-test plus ANOVA for multiple compari-
sons. Results are expressed as mean ± SEM. Statistical analy-
sis was performed using EXCEL software (Microsoft Corp.,
Redmond, WA) with P < 0:05 considered statistically signif-
icant. All the examiners were blinded to the identity of the
samples they were analysing.
3. Results and Discussion
We isolated embryonic cardiac-derived cells and demon-
strated the expression of cardiac precursor markers: Isl-1,
Nkx2.5, and GATA4 (Figures 1(a)–1(d)) and their ability to
incorporate MION as demonstrated by Prussian Blue stain-
ing (Figures 1(e) and 1(e’)). Near to 100% of the cells stained
were ISL-1+. MION incorporation would facilitate in vivo
tracking of these cells. Analysis of whole cell extract using
Western blot confirmed the expression of the abovemen-
tioned markers as well as the cardiac markers, sarcomeric
α-actinin, cardiac troponin I Western and the gap junction
protein connexin-43 (Figure 1(f)); the latter protein has been
deemed critical for the conduction of cardiac action poten-
tial. Cells were also confirmed to be c-Kit- (Figure 1(f)).
Adult Isl-1+ cardiac progenitor/stem cells can be c-Kit+ [28]
or c-Kit- cells [11]. Simpson et al. have reported that
neonatal-derived Isl-1+c-Kit+ cells have greater regenerative
ability than their adult counterparts [29]. However, few stud-
ies have utilized embryonic Isl-1+ cardiac progenitors either
c-Kit+ [30, 31] or c-Kit- [32] as we did in this study. Expres-
sion of Isl-1, Nkx2.5, and GATA4 was preserved throughout
the study, except that continued passage resulted in loss of
GATA4 expression as demonstrated by real-time PCR
(Figure 1(g)).
We also utilized the bone marrow stem cell population,
CD90+ cells. CD90 or Thy-1 is a 25–37 kDa glycosylphospha-
tidylinositol- (GPI-) anchored glycoprotein and is highly
expressed in all MSCs, irrespective of the source, and it is a
good marker for CFU-F enrichment [33]. High CD90 expres-
sion has also been related to the undifferentiated status of
MSCs, since a decrease in CD90 level can be correlated with
the temporal lineage commitment in vitro [34].
To evaluate the reparative potential of Isl-1+cells alone or
in combination with CD90+ cells, we injected cells in the
peri-infart region of rats undergoing the LAD ligation model
of MI. The biodistribution of the cells was examined by
MION labeling of Isl-1+ cells and fluorescence in situ hybrid-
ization (FISH) staining of donor-derived CD90+ cells. Prus-
sian Blue staining of paraffin embedded sections showed
that Isl-1+ cells retained MION labeling at 4-week post-MI
and that the Isl-1+cells infiltrated the fibrous tissue suggest-
ing their participation in the repair process (Figure 2(a)).
This would suggest that the MION-labelled cells migrated
into the infarcted region and remained there. We did not
observe any evidence of chroninc inflammation in the peri-
infarct or infarct area to suggest that the MION was simply
taken up by infiltrating macrophages, but rather our results
would suggest that the MION was retained within the Isl-1+
cells. Previous studies have also reported the retention of
MION particles into transplanted cells up to 28 days of
posttransplantation [35] Donor-derived CD90+ cells were
detected in and around the infarct region 4-week post-MI.
FISH for the Y chromosome (Figure 2(b), arrows) demon-
strated that CD90+cells home to the site of injury and were
found 4-week postinjection. The presence of FISH for the Y
chromosome in the 4-week samples would suggest that the
detected cells were still viable at this time point.
A critical repair response following MI is restoration of
the microvasculature in the injured area. To determine
whether administration of Isl-1+ and/or CD90+cells increased
capillarydensity in theperi-infarct region, vonWillebrand fac-
tor stainingwas performedon serial cross sections of theheart.
Unexpectedly, there was no significant increase in any of the
groups when compared to saline-injected controls (saline:
0:0388 μm2 ± 0:008 vs. sham: 0:0340 μm2 ± 0:002; p = 0:36;
saline vs. Isl-1: 0:0737 μm2 ± 0:02; p = 0:06; saline vs.
CD90+: 0:02 μm2 ± 0:005; p = 0:09; saline vs. Isl-1+/CD90+:
0:025 μm2 ± 0:01; p = 0:21). (Figures 2(c)–2(h)). This may
be because our assessment was not sensitive enough to
detect a change as we only made measurement in two
dimentions and the capillary network is an elaborate 3-
dimentional structure.
Masson’s trichrome staining of 4-week post-MI hearts
(Figure 3(a)) revealed that fibrosis was, as expected, lim-
ited to the anterior wall of the left ventricle. Surprizingly,
quantification of the fibrosis demonstrated that no cell
treatment was able to significantly reduce fibrosis when
compared to saline-treated rats (saline: 13:85% ± 0:96 vs.
Isl-1+: 10:69% ± 1:77, p = 0:14; saline vs. CD90+: 11:95% ±
1:61, p = 0:22; saline vs. Isl-1+/CD90+: 11:62% ± 1:55, p =
0:19) (Figure 3(b)). In contrast, the Isl-1+/CD90+ combina-
tion was capable of preserving wall thickness (sham:
2354:39μm± 18:03 vs. saline: 996:98μm± 120:41, p < 0:05;
sham vs. Isl-1+: 834:91 μm± 54:50, p < 0:05; sham vs.
CD90+: 1711:40 μm± 16:67, p < 0:05; sham vs. Isl-
1+/CD90+: 1841:23μm± 228:08, p = 0:02) (Figure 3(c)).
Echocardiography was used to monitor the extent of the
infarct at one and four weeks of post-MI (Figure 4(a)). Anal-
ysis of the recorded short-axis 2D and M mode images from
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Figure 2: Biodistribution of injected cells using MION labeling and FISH, showing that cell injections do not increase vascular density:
(a) Isl-1+ cells retain MION labeling, as shown by Prussian blue staining, 4 weeks following injection with cells infiltrating the scar tissue
(between yellow dotted lines) suggesting participation in the repair process. (b) Male donor-derived CD90+ cells were detected 4-week
post-MI by fluorescence in situ hybridization (FISH) for the Y chromosome shown in red (arrows). (c)–(g) Representative images from all
cohorts of cardiac tissue sections stained for von Willebrand factor. (c) sham; (d) saline; (e) Isl-1+; (f) CD90+; (g) Isl-1+/CD90+). Scale bar:
200 μm. (h) Quantification of all the sections analyzed (saline: 0:0388μm2 ± 0:008; sham: 0:0340 μm2 ± 0:002; Isl-1: 0:0737μm2 ± 0:02;
CD90+: 0:02μm2 ± 0:005; Isl-1+/CD90+: 0:025μm2 ± 0:01).
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the same rats at 1- and 4-week post-MI revealed no improve-
ment of the anterior wall contractility in the saline-treated
rats. Modest improvement of wall motion was observed in
the Isl-1+ cell-treated rats and in CD90+ cell-injected rats.
However, a complete recovery of wall contractility was
observed in the rats receiving combination of Isl-1+/CD90+
cells. The rate of LV pressure, dP/dt (max), a measure of ven-
tricular systolic contractility, improved only in the animals
treated with the Isl-1+/CD90+cell combination, restoring
cardiac function back to physiologic levels (Isl-1+/CD90+:
8982mmHg/sec ± 270 vs. sham: 10,111mmHg/sec ± 339;
p = 0:159; saline: 6910mmHg/sec ± 439 vs. sham; p < 0:05;
Isl-1+: 5971mmHg/sec ± 368 vs. sham; p < 0:05; CD90+:
6865mmHg/sec ± 130 vs. sham; p < 0:05) (Figure 4(b)).
Furthermore, dP/dt (min), a measure of ventricular dia-
stolic relaxation, showed complete restoration of cardiac
function in the combination group (Isl-1+/CD90+: −8169
mmHg/sec ± 251 vs. sham: −8992mmHg/sec ± 464; p =
0:223; saline: −6910mmHg/sec ± 1057 vs. sham; p = 0:057;
Isl-1+: −6070mmHg/sec ± 222 vs. sham; p < 0:05; CD90+: −
7028mmHg/sec ± 155 vs. sham; p < 0:05). Taken together,
administration of the Isl-1+/CD90+ cell combination follow-
ing MI improved cardiac contractility to the greatest degree
and resulted in improved functional outcomes compared to
either cell type alone.
One limitation of this report is that it represents a single-
dose study; therefore, the observed lack of benefit of either
Isl-1+ or CD90+ type alone could be due to insufficient num-
bers. Furthermore, the beneficial effect we observed in the
combination cell experiment may be due to the injection of
two million cells instead of one million. Future studies are
needed to test the efficacy of multiple doses and different pro-
portions of each test population per dose. With repeated
injections of the individual populations, efficacy in the end-
points examined may occur. Eventhough CD90+cells alone
did not provide functional benefit, the cells were detectable
four weeks post-MI suggesting that their prolonged survival
offered paracrine support to the Isl-1+ cells, in turn, fostering
their survival and function. The Isl-1+ cells when injected
expressed Nkx2.5, GATA4, α-sarcomeric actin, cardiac tro-
ponin-I, and connexin 43 and represented immature cardio-
myocytes that were progressing towards linage specification;
however, we did not determine that the cells actually differ-
entiated into cardiomyocytes in vivo and the beneficial
effect we observed may likely be due to the paracrine pro-
duction of these cells. Future studies may consider the use
of Isl-1+ cells with different levels of differentiation and
the use of fluorescently labeled Isl-1+ cells to facilitate track-
ing and colocalization with cardiomyocyte specific markers
to establish whether the Isl-1+cells can differentiate in vivo
to cardiomyocytes.
With the wide spread utilization of iPSC technology and
now initiation of clinical trials utilizing these cells, the possi-
bility of generating large numbers of cells with fetal pheno-
types and surface markers is now possible. Moretti et al.
generated Isl1 cells from iPSC making the transition to
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Figure 3: Combination of Isl-1+ cells/CD90+ cells preserves wall thickness. (a) Masson’s trichrome staining was used to stain the fibrotic
tissue in blue. Representative bright field microscopy images of 4-week post-MI rat hearts are shown. Fibrosis is limited to the anterior
wall of the left ventricle. (b) Quantification of fibrosis revealed that none of the cell treatments was able to significantly reduce fibrosis
(saline: 13:85% ± 0:96 vs. Isl-1+: 10:69% ± 1:77, p = 0:14; saline vs. CD90+: 11:95% ± 1:61, p = 0:22; saline vs. Isl-1+/CD90+: 11:62% ± 1:55,
p = 0:19). The combination of Isl-1+cells and CD90+ cell treatment was sufficient to maintain wall thickness (sham: 2354:39 μm± 18:03 vs.
saline: 996:98μm± 120:41, p < 0:05; sham vs. Isl-1+: 834:91 μm± 54:50, p < 0:05; sham vs. CD90+: 1711:40μm± 16:67, p < 0:05; sham vs.
Isl-1+/CD90+: 1841:23 μm± 228:08, p = 0:02) (c).
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Figure 4: Combination of Isl-1+cells and CD90+ cells leads to improved cardiac function, and schematic representation of combination stem
cell administration on cardiac repair following LAD ligation induced MI. (a) Representative screenshots of echocardiograms at 1- and 4-week
post-MI time points in all the four treatment groups (saline, Isl-1+, CD90+, and Isl-1+/CD90+). (b) Hemodynamic parameter assessment by
Millar catheterization revealed that the combination therapy group demonstrated a significant improvement of cardiac function compared to
either monotherapy. There was no significant difference between Isl-1+/CD90+ and sham. (c) Isl-1+ cells derived from mouse embryos and
adult bone marrow-derived CD-90+ cells work in combination to restore cardiac function and preserve wall thickness in the LAD ligation
model of MI. In vivo cells work in synergy to carry out healing and the use of two cell types may serve to optimize outcomes both for the
target tissue in need of repair and for facilitating donor cell survival.
9Stem Cells International
generation of patient specific Isl-1+ cells feasible [36]. Fur-
thermore, the use of SSEA5- iPSCs reduces the risk of terato-
mas making the transition of iPSC technology to clinical
trials more achievable [37].
4. Conclusions
In summary, Isl-1+/CD90+ cell combination restored cardiac
function and preserved wall thickness in the rat MI model
and provides support for the consideration of combinations
of cells for therapeutic interventions. In vivo, cells work in
synergy to carry out healing and the use of two cell types
may serve to optimize outcomes both for the target tissue
in need of repair and for facilitating donor cell survival.
Determining which cell combinations function optimally
for a particular disease or injury model will represent a
new challenge.
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